Key Findings:  This case study is of an individual who had been successfully managing symptoms of Autism spectrum disorder with antipsychotics and oral cannabidiol (CBD), but as they aged, the current treatment became insufficient. Increasing dosing also did not improve symptoms; however, fortification of the CBD with anxiolytic and calming terpenes eventually lessened and eliminated the aggressive behaviors, suggesting the terpene profile and ratio may have more of an impact on symptom control.
Type of Study:  Meta-analysis
Study Sample Size:  1
Study Result:  Positive
Study Location(s):  Israel, Italy
Year of Pub:  2022
Cannabinoids Studied:  Cannabidiol (CBD), Tetrahydrocannabinol (THC), Anandamide (AEA), Fatty Acid Amide Hydrolase (FAAH)
Phytocannabinoid Source:  Cannabis Flower derived
Chemotype:  Chemotype III
Terpenes Studied:  ß-Caryophyllene, Limonene, Linalool, Nerolidol, Pinene
Receptors Studied:  CB1, CB2, GPCR 55, TRPV1, TRPV2, PPAR - Gamma, TRPs, PPARs
Ligands Studied:  Dopamine, Oxytocin, Serotonin
Dosage: Terpene enriched CBD (0.19 mg/kg of body weight)
Route of Administration:  Oral (Ingestion)